Overview
* Perrigo Q3 2025 net sales down 4.1%, missing analyst expectations
* Adjusted EPS for Q3 2025 beats analyst estimates
* Company updates FY 2025 outlook due to industry dynamics and market trends
Outlook
* Perrigo ( PRGO ) revises 2025 outlook due to infant formula dynamics and soft OTC trends
* Company expects 2025 adjusted EPS of $2.70 to $2.80, up 5% to 9%
* Perrigo ( PRGO ) forecasts 2025 net sales growth of -2.5% to -3.0%
Result Drivers
* OTC MARKET SHARE GAINS - Perrigo ( PRGO ) achieved dollar, unit, and volume share gains in five of seven OTC store brand categories despite soft market consumption trends
* STRATEGIC BUSINESS REVIEWS - Ongoing strategic reviews of Infant Formula and Oral Care businesses, with a focus on portfolio evaluation
* CURRENCY AND COST MANAGEMENT - Favorable currency translation and disciplined cost management partially offset declines in adjusted operating income
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Sales Miss $1.04 $1.09
bln bln (3
Analysts
)
Q3 Beat $0.80 $0.75 (3
Adjusted Analysts
EPS )
Q3 EPS $0.09
Q3 Beat $173 mln $168.60
Adjusted mln (3
Operatin Analysts
g Income )
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the pharmaceuticals peer group is "buy"
* Wall Street's median 12-month price target for Perrigo Company PLC ( PRGO ) is $32.00, about 36.9% above its November 4 closing price of $20.19
* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release:
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
